Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 27 Researches
8
USERS' SCORE
Moderately Good
Based on 50 Reviews
7.7
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Wild Caught Fish Oil Concentrate
1250 mg
†
Total Omega-3 Fatty Acids as TG
1055 mg
†
EPA (Eicosapentaenoic Acid)
690 mg
†
DHA (Docosahexaenoic Acid)
310 mg
†
Other Omega-3 Fatty Acids
55 mg
†
Top Medical Research Studies
9
We investigated how eicosapentaenoic acid (EPA) may help improve heart health after a heart attack. In our study, we induced myocardial infarction (MI) in male rats by ligating their coronary artery. Some of these rats received daily treatment with EPA, while others did not, allowing us to compare the effects.
Over 12 weeks, we observed that the rats treated with EPA showed better left ventricular function—essentially, their hearts were working more efficiently. Moreover, these rats had higher levels of EPA in their mitochondria, which are the energy factories of cells. Despite the damage caused by the heart attack, the EPA treatment helped maintain crucial energy levels and kept the mitochondrial function from declining, preserving a specific protein linked to cellular health.
Our findings suggest that including EPA in the diet can bolster mitochondrial quality and support heart function after an MI. This could mean that EPA may serve as an important dietary addition for promoting heart health following heart events.
Over 12 weeks, we observed that the rats treated with EPA showed better left ventricular function—essentially, their hearts were working more efficiently. Moreover, these rats had higher levels of EPA in their mitochondria, which are the energy factories of cells. Despite the damage caused by the heart attack, the EPA treatment helped maintain crucial energy levels and kept the mitochondrial function from declining, preserving a specific protein linked to cellular health.
Our findings suggest that including EPA in the diet can bolster mitochondrial quality and support heart function after an MI. This could mean that EPA may serve as an important dietary addition for promoting heart health following heart events.
Read More
9
DHA aids post-heart attack recovery
We explored the effects of docosahexaenoic acid (DHA) on heart attack recovery in rats. The study aimed to understand how DHA, alongside eicosapentaenoic acid (EPA), can influence heart failure following myocardial infarction (MI).
Using several groups of rats experiencing moderate heart issues, we evaluated how these omega-3 fatty acids impacted heart function. We found that both DHA and EPA effectively curtailed the hypertrophic response in heart cells. This response is a significant factor in heart failure, where heart tissue thickens and hardens.
Notably, both DHA and EPA inhibited the activity of a histone acetyltransferase called p300. This activity is linked to molecular changes that promote heart cell enlargement and fibrosis. In our analysis, we observed that these fatty acids not only preserved cardiac function but also prevented structural changes common after a heart attack.
Overall, we noted that DHA had a comparable protective effect to EPA, significantly improving heart health and reducing fibrosis in the heart tissue. As such, the findings suggest that incorporating DHA could be a heart-friendly choice post-heart attack.
Using several groups of rats experiencing moderate heart issues, we evaluated how these omega-3 fatty acids impacted heart function. We found that both DHA and EPA effectively curtailed the hypertrophic response in heart cells. This response is a significant factor in heart failure, where heart tissue thickens and hardens.
Notably, both DHA and EPA inhibited the activity of a histone acetyltransferase called p300. This activity is linked to molecular changes that promote heart cell enlargement and fibrosis. In our analysis, we observed that these fatty acids not only preserved cardiac function but also prevented structural changes common after a heart attack.
Overall, we noted that DHA had a comparable protective effect to EPA, significantly improving heart health and reducing fibrosis in the heart tissue. As such, the findings suggest that incorporating DHA could be a heart-friendly choice post-heart attack.
Read More
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
Read More
Most Useful Reviews
9
Significant improvement
2 people found this helpful
After three months of use, I noticed a significant improvement in my memory quality, mental presence, and heart health. The ingredients are gentle on my stomach and did not cause any digestion issues. The packaging is well done, maintaining the product's texture and taste.
Read More
9
Prevents heart blockage
1 people found this helpful
I've been taking SR Triple Strength Fish Oil for over 10 years, even after two angiograms that showed false positives. My doctor assures me that my heart and arteries are in great shape for another decade without blockages. I'm truly confident and satisfied with this remarkable supplement.
Read More
9
Positive heart impact
1 people found this helpful
Excellent omega from a reputable manufacturer. One of the best on the site, it is vital for your diet and should be taken in courses, 2-3 times a year with a break of several months. I take one capsule each day with a fat-rich breakfast. Omega is a staple for my family. It positively affects heart health, reduces inflammation, maintains healthy skin and hair, and lowers bad cholesterol. There’s no pronounced taste, the quality is excellent, the size is suitable, and there are no issues with swallowing the capsule.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 27 Researches
8
- All Researches
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
Read More
9
We explored the role of eicosapentaenoic acid (EPA) in heart attack recovery, particularly its effect on restoring blood flow during ST-elevation myocardial infarction (STEMI). Our focus was on understanding whether higher levels of EPA relative to arachidonic acid could lead to faster recovery and better outcomes for patients experiencing this type of heart attack.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
Read More
9
We explored how eicosapentaenoic acid (EPA) and its metabolites can protect heart cells during a heart attack, specifically focusing on a laboratory model for ischemic injury. Our investigation centered on a specific receptor found in heart cells, known as the Free Fatty Acid Receptor 4 (Ffar4).
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
Read More
9
Significant heart attack risk reduction
In this extensive study involving nearly 5,800 patients with atherosclerotic cardiovascular disease (ASCVD) and high triglyceride levels, we explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing the risk of major adverse cardiovascular events (MACE) like heart attacks.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Read More
9
We explored the cardiovascular benefits of eicosapentaenoic acid, specifically through a substance called icosapent ethyl (IPE), in individuals with elevated levels of lipoprotein(a). This post hoc analysis took place in a study called REDUCE-IT, which involved over 8,000 participants who were either battling established cardiovascular disease or were at high risk due to diabetes and other factors.
Participants in the study were given either IPE or a placebo while maintaining their statin therapy. We observed that elevated lipoprotein(a) concentrations were linked to an increased risk of major adverse cardiovascular events, even when low-density lipoprotein cholesterol was managed well.
Importantly, IPE demonstrated a consistent ability to lower the risk of these heart issues among participants, regardless of their lipoprotein(a) levels. This effect was particularly noticeable for those with elevated lipoprotein(a), showing that IPE could be beneficial in managing cardiovascular risk in this group.
Overall, the findings highlight the potential of eicosapentaenoic acid as a valuable treatment option for reducing heart attack risk in high-risk patients, emphasizing its importance alongside traditional therapies.
Participants in the study were given either IPE or a placebo while maintaining their statin therapy. We observed that elevated lipoprotein(a) concentrations were linked to an increased risk of major adverse cardiovascular events, even when low-density lipoprotein cholesterol was managed well.
Importantly, IPE demonstrated a consistent ability to lower the risk of these heart issues among participants, regardless of their lipoprotein(a) levels. This effect was particularly noticeable for those with elevated lipoprotein(a), showing that IPE could be beneficial in managing cardiovascular risk in this group.
Overall, the findings highlight the potential of eicosapentaenoic acid as a valuable treatment option for reducing heart attack risk in high-risk patients, emphasizing its importance alongside traditional therapies.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 50 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
9
Significant improvement
2 people found this helpful
After three months of use, I noticed a significant improvement in my memory quality, mental presence, and heart health. The ingredients are gentle on my stomach and did not cause any digestion issues. The packaging is well done, maintaining the product's texture and taste.
Read More
9
Prevents heart blockage
1 people found this helpful
I've been taking SR Triple Strength Fish Oil for over 10 years, even after two angiograms that showed false positives. My doctor assures me that my heart and arteries are in great shape for another decade without blockages. I'm truly confident and satisfied with this remarkable supplement.
Read More
9
Positive heart impact
1 people found this helpful
Excellent omega from a reputable manufacturer. One of the best on the site, it is vital for your diet and should be taken in courses, 2-3 times a year with a break of several months. I take one capsule each day with a fat-rich breakfast. Omega is a staple for my family. It positively affects heart health, reduces inflammation, maintains healthy skin and hair, and lowers bad cholesterol. There’s no pronounced taste, the quality is excellent, the size is suitable, and there are no issues with swallowing the capsule.
Read More
9
Effective heart support
Sports Research Omega-3 Fish Oil is a triple potency product for heart and joint support. It offers a solid quality with clear dosage recommendations enhancing its usability. The higher concentration of omega-3 fatty acids is notably beneficial for heart health. The bottle size is fitting and lasts sufficiently. I recommend it for anyone seeking effective heart health support.
Read More
9
Lowering cholesterol
The quality ingredients are excellent, and the packaging is good. The effect is unbelievably positive for heart health and lowers cholesterol levels without tasting fishy.
Read More
Frequently Asked Questions
7.5
Enhances heart function
1 people found this helpful
The quality of this omega-3 is outstanding. After two months of use, I've observed a reduction in cholesterol, and it strengthens both my heart and hair. The taste is somewhat acceptable, and it alleviates skin inflammation. This product is suitable for all ages, and the packaging is superb, ensuring safe storage.
9
Effective for joints
1 people found this helpful
One of the most effective Omegas, the high dose delivers noticeable results quickly. Within days, my heart didn’t bother me at night, and my joints felt less discomfort. I highly recommend this high-quality omega-3!
9
Significant improvement
2 people found this helpful
After three months of use, I noticed a significant improvement in my memory quality, mental presence, and heart health. The ingredients are gentle on my stomach and did not cause any digestion issues. The packaging is well done, maintaining the product's texture and taste.
9
Strengthened heart
1 people found this helpful
I've noticed significant improvement in my heart health—reduced cholesterol and a stronger heart. I feel more energised and my skin has improved. This product contains omega-3s, with fish oils providing more health benefits than plant-based sources. There are no issues with smell or taste and it’s easy to take, although large capsules could be a consideration for some. I trust this product to deliver great benefits and highly recommend it.
7.5
Eases inflammation
1 people found this helpful
Certifying that fish oil reduces inflammation and benefits heart health, I enjoy it alongside lutein for eye protection. I will certainly repurchase it!
7.5
Improves heart health
11 people found this helpful
Omega 3 is excellent for enhancing health, particularly for the heart and arteries, and it aids in cholesterol management. I've been using it consistently, despite the limited availability and high cost in my country. Prescribed by my doctor, I can attest to its quality, particularly due to its omega-3 content. Vitamins E Mix offers strength, protection, and vitality.
7.5
Heart and skin care
1 people found this helpful
Good manufacturer. Great product. I take one capsule daily, and it is effective for heart health, skin, hair, etc.
7.5
Improves heart health
7 people found this helpful
Just a great omega! The large packaging is excellent quality and will last for 3 months since I take 2 capsules daily to meet the 1500-2000 mg dosage. This omega positively influences heart function, enhances hair quality, helps manage cholesterol levels, and may reduce inflammation in the body.
9
Normalised cholesterol levels
1 people found this helpful
This omega is fantastic! I frequently buy vitamins from this brand, which consistently deliver results. The quality is superb. One capsule provides the dosage of three standard ones. A cardiologist advised this omega for cholesterol management and to support heart function. After a course, my cholesterol normalised. The packaging is also great for quick access.
9
Significant heart attack risk reduction
In this extensive study involving nearly 5,800 patients with atherosclerotic cardiovascular disease (ASCVD) and high triglyceride levels, we explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing the risk of major adverse cardiovascular events (MACE) like heart attacks.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
Patients were randomly assigned to receive either icosapent ethyl or a placebo, with their health monitored over a median follow-up of nearly five years. The results were promising: we noticed a significant reduction in MACE in the group receiving icosapent ethyl compared to those on placebo.
Specifically, there were 361 instances of MACE in the icosapent ethyl group versus 489 in the placebo group. This translates to a 28% lower risk of events like heart attacks or strokes for those taking icosapent ethyl. Furthermore, we observed that the absolute benefits were greatest for patients with higher baseline cardiovascular risk.
Overall, regardless of their initial risk levels, using icosapent ethyl showed an impressive potential to decrease the risk of major cardiovascular issues, including heart attacks. This study underscores the value of incorporating eicosapentaenoic acid into treatment plans for patients at risk of heart disease.
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
9
We explored the role of eicosapentaenoic acid (EPA) in heart attack recovery, particularly its effect on restoring blood flow during ST-elevation myocardial infarction (STEMI). Our focus was on understanding whether higher levels of EPA relative to arachidonic acid could lead to faster recovery and better outcomes for patients experiencing this type of heart attack.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
We assessed the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, in patients who recently suffered a heart attack. In a study involving older adults aged 70 to 82, participants were given either 1.8 grams of EPA/DHA daily or a placebo over two years.
Throughout the trial, we tracked the emergence of new atrial fibrillation (AF) and 'micro-AF' through clinical observations and advanced screening methods. Our findings revealed that among those taking the EPA supplement, 11.9% developed AF or 'micro-AF', compared to just 6.5% in the placebo group. This led us to conclude that the risk of both conditions appeared to rise in those supplementing with omega-3 fatty acids after a heart attack.
Interestingly, we also discovered that increases in serum EPA levels played a significant role, accounting for about 65% of the observed association with AF risk. Thus, while EPA was expected to help heart health, our findings suggest it might actually increase the chances of heart rhythm issues in post-heart attack patients. It's essential for individuals and healthcare providers to consider these results when thinking about treatments following a heart attack.
Throughout the trial, we tracked the emergence of new atrial fibrillation (AF) and 'micro-AF' through clinical observations and advanced screening methods. Our findings revealed that among those taking the EPA supplement, 11.9% developed AF or 'micro-AF', compared to just 6.5% in the placebo group. This led us to conclude that the risk of both conditions appeared to rise in those supplementing with omega-3 fatty acids after a heart attack.
Interestingly, we also discovered that increases in serum EPA levels played a significant role, accounting for about 65% of the observed association with AF risk. Thus, while EPA was expected to help heart health, our findings suggest it might actually increase the chances of heart rhythm issues in post-heart attack patients. It's essential for individuals and healthcare providers to consider these results when thinking about treatments following a heart attack.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Yamada R, Uematsu M, Nakamura T, Kobayashi T, Horikoshi T, et al. Elevated eicosapentaenoic acid to arachidonic acid ratio and rapid coronary blood flow restoration in ST-elevation myocardial infarction. Hellenic J Cardiol. 2025. doi:10.1016/j.hjc.2025.01.003
- Puccini SJ, Healy CL, Harsch BA, Ahmed AR, Shearer GC, et al. A Cell Autonomous Free fatty acid receptor 4 - ChemR23 Signaling Cascade Protects Cardiac Myocytes from Ischemic Injury. bioRxiv. 2025. doi:10.1101/2024.11.26.625260
- Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. doi:10.1161/CIRCULATIONAHA.123.065520
- Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. doi:10.1093/eurjpc/zwae184
- Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, et al. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. Eur Heart J Cardiovasc Pharmacother. 2024;10:488. doi:10.1093/ehjcvp/pvae030
- Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024;83:1529. doi:10.1016/j.jacc.2024.02.016
- Sabbour H, Bhatt DL, Elhenawi Y, Aljaberi A, Bennani L, et al. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovasc Drugs Ther. 2024. doi:10.1007/s10557-023-07519-z
- Bernhard B, Heydari B, Abdullah S, Francis SA, Lumish H, et al. Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial. Int J Cardiol. 2024;399:131698. doi:10.1016/j.ijcard.2023.131698
- Le VT, Knight S, Watrous JD, Najhawan M, Dao K, et al. Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Front Cardiovasc Med. 2023;10:1229130. doi:10.3389/fcvm.2023.1229130
- Myhre PL, Berge T, Kalstad AA, Tveit SH, Laake K, et al. Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial. Clin Nutr. 2023;42:1657. doi:10.1016/j.clnu.2023.07.002
- Borghi C, Bragagni A. Clinical results and mechanism of action of icosapent ethyl. Eur Heart J Suppl. 2023;25:B37. doi:10.1093/eurheartjsupp/suad088
- Chiusolo S, Bork CS, Gentile F, Lundbye-Christensen S, Harris WS, et al. Adipose tissue n-3/n-6 fatty acids ratios versus n-3 fatty acids fractions as predictors of myocardial infarction. Am Heart J. 2023;262:38. doi:10.1016/j.ahj.2023.03.019
- Rabbat MG, Lakshmanan S, Benjamin MM, Doros G, Kinninger A, et al. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Heart J Cardiovasc Imaging. 2023;24:866. doi:10.1093/ehjci/jead063
- Kobara M, Shiraishi T, Noda K, Toba H, Nakata T. Eicosapentaenoic Acid Preserves Mitochondrial Quality and Attenuates Cardiac Remodeling After Myocardial Infarction in Rats. J Cardiovasc Transl Res. 2023;16:816. doi:10.1007/s12265-023-10363-z
- Luo X, Liu M, Wang S, Chen Y, Bao X, et al. Combining metabolomics and OCT to reveal plasma metabolic profiling and biomarkers of plaque erosion and plaque rupture in STEMI patients. Int J Cardiol. 2023;390:131223. doi:10.1016/j.ijcard.2023.131223
- Bork CS, Lundbye-Christensen S, Venø SK, Lasota AN, Tjønneland A, et al. Intake of marine and plant-derived n-3 fatty acids and development of atherosclerotic cardiovascular disease in the Danish Diet, Cancer and Health cohort. Eur J Nutr. 2023;62:1389. doi:10.1007/s00394-022-03081-w
- Park GH, Cho JH, Lee D, Kim Y. Association between Seafood Intake and Cardiovascular Disease in South Korean Adults: A Community-Based Prospective Cohort Study. Nutrients. 2022;14. doi:10.3390/nu14224864
- Bassuk SS, Manson JE. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence. Cardiovasc Res. 2023;119:1297. doi:10.1093/cvr/cvac172
- Alfaddagh A, Kapoor K, Dardari ZA, Bhatt DL, Budoff MJ, et al. Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis. 2022;353:11. doi:10.1016/j.atherosclerosis.2022.06.1018
- Sunagawa Y, Katayama A, Funamoto M, Shimizu K, Shimizu S, et al. The polyunsaturated fatty acids, EPA and DHA, ameliorate myocardial infarction-induced heart failure by inhibiting p300-HAT activity in rats. J Nutr Biochem. 2022;106:109031. doi:10.1016/j.jnutbio.2022.109031
- Halade GV, Kain V, De La Rosa X, Lindsey ML. Metabolic transformation of fat in obesity determines the inflammation resolving capacity of splenocardiac and cardiorenal networks in heart failure. Am J Physiol Heart Circ Physiol. 2022;322:H953. doi:10.1152/ajpheart.00684.2021
- Shi Y, Li H, Wu T, Wang Q, Zhu Q, et al. Docosahexaenoic Acid-Enhanced Autophagic Flux Improves Cardiac Dysfunction after Myocardial Infarction by Targeting the AMPK/mTOR Signaling Pathway. Oxid Med Cell Longev. 2022;2022:1509421. doi:10.1155/2022/1509421
- Wang CP, Lee CC, Wu DY, Chen SY, Lee TM. Differential effects of EPA and DHA on PPARγ-mediated sympathetic innervation in infarcted rat hearts by GPR120-dependent and -independent mechanisms. J Nutr Biochem. 2022;103:108950. doi:10.1016/j.jnutbio.2022.108950
- Myhre PL, Kalstad AA, Tveit SH, Laake K, Schmidt EB, et al. Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial. J Intern Med. 2022;291:637. doi:10.1111/joim.13442
- Pertiwi K, Küpers LK, de Goede J, Zock PL, Kromhout D, et al. Dietary and Circulating Long-Chain Omega-3 Polyunsaturated Fatty Acids and Mortality Risk After Myocardial Infarction: A Long-Term Follow-Up of the Alpha Omega Cohort. J Am Heart Assoc. 2021;10:e022617. doi:10.1161/JAHA.121.022617
